Literature DB >> 1716693

Identification and mapping of neutralizing epitopes of human parvovirus B19 by using human antibodies.

H Sato1, J Hirata, N Kuroda, H Shiraki, Y Maeda, K Okochi.   

Abstract

We identified and mapped the regions responsible for neutralization in the human parvovirus B19 structural protein by using region-specific human antibodies derived from seropositive blood donors. The region-specific antibodies were purified by using affinity columns coupled with synthetic peptides of the hydrophilic regions including the beta-turn structure deduced by the predicted secondary structure of VP2. Fifteen highly specific antibodies against the synthetic peptides were obtained. Ten of them were able to precipitate the radiolabeled virus. Six of them proved to be able to protect the colony-forming unit erythroid cells in human bone marrow cell cultures from injury by the virus. The sequences recognized by the six neutralizing antibodies were sites corresponding to amino acids 253 to 272, 309 to 330, 325 to 346, 359 to 382, 449 to 468, and 491 to 515 from the amino-terminal portion of VP2. These observations suggest that the neutralizing epitopes were distributed in the region from amino acid 253 in the amino-terminal portion of VP2 to the carboxyl terminus of VP2.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1716693      PMCID: PMC249042     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  29 in total

1.  Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments.

Authors:  S F Cotmore; V C McKie; L J Anderson; C R Astell; P Tattersall
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

2.  Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisis.

Authors:  R O Shade; M C Blundell; S F Cotmore; P Tattersall; C R Astell
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

3.  Prediction of protein conformation.

Authors:  P Y Chou; G D Fasman
Journal:  Biochemistry       Date:  1974-01-15       Impact factor: 3.162

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Identification of the region including the epitope for a monoclonal antibody which can neutralize human parvovirus B19.

Authors:  H Sato; J Hirata; M Furukawa; N Kuroda; H Shiraki; Y Maeda; K Okochi
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

6.  Novel transcription map for the B19 (human) pathogenic parvovirus.

Authors:  K Ozawa; J Ayub; Y S Hao; G Kurtzman; T Shimada; N Young
Journal:  J Virol       Date:  1987-08       Impact factor: 5.103

7.  Parvovirus-like particles in human sera.

Authors:  Y E Cossart; A M Field; B Cant; D Widdows
Journal:  Lancet       Date:  1975-01-11       Impact factor: 79.321

8.  Human parvovirus-associated arthritis: a clinical and laboratory description.

Authors:  D M Reid; T M Reid; T Brown; J A Rennie; C J Eastmond
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

9.  Human parvovirus arthropathy.

Authors:  D G White; A D Woolf; P P Mortimer; B J Cohen; D R Blake; P A Bacon
Journal:  Lancet       Date:  1985-02-23       Impact factor: 79.321

10.  Hypothesis: the aplastic crisis of hereditary spherocytosis is due to a single transmissible agent.

Authors:  P P Mortimer
Journal:  J Clin Pathol       Date:  1983-04       Impact factor: 3.411

View more
  23 in total

1.  Unique region of the minor capsid protein of human parvovirus B19 is exposed on the virion surface.

Authors:  S J Rosenfeld; K Yoshimoto; S Kajigaya; S Anderson; N S Young; A Field; P Warrener; G Bansal; M S Collett
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

2.  Parvovirus diagnostics and vaccine production in insect cells.

Authors:  J I Casal
Journal:  Cytotechnology       Date:  1996-01       Impact factor: 2.058

3.  Mapping Antigenic Epitopes on the Human Bocavirus Capsid.

Authors:  Shweta Kailasan; Jamie Garrison; Maria Ilyas; Paul Chipman; Robert McKenna; Kalle Kantola; Maria Söderlund-Venermo; Indrė Kučinskaitė-Kodzė; Aurelija Žvirblienė; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

4.  Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions.

Authors:  T Saikawa; S Anderson; M Momoeda; S Kajigaya; N S Young
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

5.  Subunit interaction in B19 parvovirus empty capsids.

Authors:  S J Rosenfeld; N S Young; D Alling; J Ayub; C Saxinger
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

Review 6.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

7.  Characterization of Parvovirus B19 genotype 2 in KU812Ep6 cells.

Authors:  Johannes Blümel; Anna Maria Eis-Hübinger; Albert Stühler; Claudia Bönsch; Matthias Gessner; Johannes Löwer
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

8.  Cottontail rabbit papillomavirus L1 protein-based vaccines: protection is achieved only with a full-length, nondenatured product.

Authors:  Y L Lin; L A Borenstein; R Ahmed; F O Wettstein
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

9.  Human monoclonal antibodies for the immunological characterization of a highly conserved protein domain of the hepatitis C virus glycoprotein E1.

Authors:  K Siemoneit; M da S Cardoso; K Koerner; A Wölpl; B Kubanek
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

Review 10.  Parvovirus B19 infection.

Authors:  J R Kerr
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.